glp-1 agonists drug class Adverse effects of drugs. Gastrointestinal issues are GLP-1 Receptor Agonists in Pregnancy

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that showed up to 24.2% weight loss in phase 2 trials at 48 weeks, potentially exceeding both CagriSema and tirzepatide

Clinical trials and meta-analyses consistently show that DPP-4 inhibitors produce a modest but clinically meaningful reduction in HbA1c , typically in the range of: 0.5% to 1.0% (approximately 5.5 to 11 mmol/mol) when used as monotherapy or add-on therapy Reductions at the higher end of this range are more likely when baseline HbA1c is significantly elevated For example, sitagliptin has demonstrated reductions of around 0.60.8% in randomised controlled trials, while vildagliptin and saxagliptin show broadly comparable efficacy

Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met

Is this treatment suitable for all skin types